RxDoctor Payments Data

Ryanne Clarke

Family · Gretna, LANPI 1770911406

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $73,839 of the $122,580 with a category attached, or 60.2%. Gilead accounts for 95.6% of it on its own, with 24 other manufacturers making up the rest. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$122,580in general payments, 2019–2025

Across 525 payments — averaging $233.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$117K
  • Viiv Healthcare Company$2K
  • Merck$432
  • AbbVie$300
  • Abbott$290
  • Johnson & Johnson$257
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$5,6905%
  • Speaking & faculty fees$73,83960%
  • Travel & lodging$30,44925%
  • Food & beverage$12,59110%
  • Education$110%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,580 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala38$156,266
DovatoDolutegravir Sodium/Lamivudine23$53,845
Albuterol Sulfate HfaAlbuterol Sulfate14$318
Pravastatin Sodium13$174
Fluticasone Propionate14$140
Amlodipine Besylate18$114
Hydroxyzine Pamoate11$53
Glipizide11$30
Hydrochlorothiazide11$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$117,151$156,26638 claims
Viiv Healthcare CompanyDovato$2,212$53,84523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Gretna

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →